Dolby SVP John Couling sells 7,273 shares in insider trade

Dolby Laboratories, Inc. executive John Couling, senior vice president of Entertainment, reported selling 7,273 shares of Class A common stock at $68.75 per share on 12/11/2025.

Rhea-AI Filing Summary

Dolby Laboratories, Inc. executive John Couling, senior vice president of Entertainment, reported selling 7,273 shares of Class A common stock at $68.75 per share on 12/11/2025.

After this insider sale, he beneficially owned 108,065 Class A shares directly, including 48,526 shares underlying restricted stock units that are subject to forfeiture until they vest.

Insider Trade Summary

Net Seller: 7,273 shares

Net Sell 1 txn

Insider Couling John D

Role SVP, Entertainment

Sold 7,273 shs ($500K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	7,273	$68.75	$500K

Holdings After Transaction: Class A Common Stock — 108,065 shares (Direct)

Footnotes (1)

1. F1. Shares held following the reported transaction includes 48,526 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dolby Laboratories (DLB) report for John Couling?

John Couling reported an insider sale of 7,273 shares of Dolby Laboratories Class A common stock on 12/11/2025 at a price of $68.75 per share.

What is John Couling's role at Dolby Laboratories (DLB)?

John Couling is an officer of Dolby Laboratories, serving as SVP, Entertainment, as indicated in the filing.

How many Dolby (DLB) shares does John Couling hold after the reported sale?

Following the transaction, John Couling beneficially owned 108,065 shares of Dolby Laboratories Class A common stock in direct ownership.

How many of John Couling's Dolby (DLB) shares are tied to restricted stock units?

Of the shares held after the transaction, 48,526 represent Dolby Laboratories Class A shares underlying restricted stock units that are subject to forfeiture until they vest.

What type of security did John Couling sell in this Dolby (DLB) Form 4?

The reported transaction involved Dolby Laboratories Class A common stock, with 7,273 shares disposed of in a sale.

Is this Dolby (DLB) Form 4 filed for one reporting person or multiple?

The Form 4 is indicated as being filed by one reporting person, covering John Couling only.

Were any derivative securities reported for John Couling in this Dolby (DLB) filing?

The section for derivative securities (Table II) in the provided content does not list any derivative transactions or holdings for John Couling.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/15/2025 - 05:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Couling John D

(Last) (First) (Middle)

C/O DOLBY LABORATORIES, INC.

1275 MARKET STREET

(Street)

SAN FRANCISCO CA 94103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dolby Laboratories, Inc. [ DLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Entertainment

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	12/11/2025		S		7,273	D	$68.75	108,065(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares held following the reported transaction includes 48,526 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest.

	/s/ Daniel Rodriguez as Attorney-in-Fact for John Couling	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.